Moderna Vaccine Appears to Offer Strongest Protection Against COVID

According to a new report from the Centers for Disease Control and Prevention, two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 U.S. hospitals during the period between March 11 and August 15.

Vaccine effectiveness against COVID-19 hospitalization for Moderna and Pfizer-BioNTech doses were 93 percent and 88 percent, respectively, whereas the single-dose Janssen [Johnson & Johnson] vaccine had a lower effectiveness rate at 71 percent.

Protection for the Pfizer-BioNTech vaccine declined four months after vaccination. Released Friday, September 17, the report revealed that individuals vaccinated with the Janssen vaccine also had lower postvaccination anti-SARS-

CoV-2 antibody levels than did recipients of mRNA vaccines.

In addition, although an immunologic correlate of protection has not been established for COVID-19 vaccines, the researchers found that antibody titers after infection and vaccination have been associated with protection.

"These real-world data suggest that the 2-dose Moderna and Pfizer-BioNTech mRNA vaccine regimens provide more protection than does the 1-dose Janssen viral vector vaccine regimen," the researchers wrote.

"Although the Janssen vaccine had lower observed vaccine effectiveness, one dose of Janssen vaccine still reduced risk for COVID-19-associated hospitalization by 71 percent." The study included 3,689 patients.

Overall, 2,362 (64

Continue reading online at: thewestsidegazette.com